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Selective Serotonin Reuptake Inhibitors in Pediatric
Depression: Is the Balance Between Benefits and
Risks Favorable?
Christopher J. Kratochvil, M.D.,1 Benedetto Vitiello, M.D.,2 John Walkup, M.D.,3
Graham Emslie, M.D.,4 Bruce D. Waslick, M.D.,5 Elizabeth B. Weller, M.D.,6
William J. Burke, M.D.,1 and John S. March, M.D.7

ABSTRACT
Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs)
have highlighted the need to reassess potential benefits, as well as potential risks of this class of
medications in the treatment of pediatric depression. The recent availability of data from metaanalyses of published and unpublished antidepressant trials, epidemiological studies, and the
Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this
risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have arrived at rather disparate conclusions regarding the data, resulting in continued controversy. Although all groups appear to agree that careful assessment, education regarding risks, and closer
monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the
U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable
risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that
the SSRIs should not be used in the treatment of depression in children and adolescents. The
authors of this review have taken into consideration many of these same data and offer a critical
discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded
that SSRIs—in particular, fluoxetine—do have a role in the treatment of pediatric depression.

INTRODUCTION

concerns have arisen intermittently over the
past decade regarding the safety of the SSRIs
in the treatment of MDD. Whereas in adults
the well-documented efficacy of SSRIs ensures
a favorable risk/benefit balance, the paucity of
information in the pediatric population has
made it difficult for clinicians and regulators
to reach the same conclusion in youths. The

T

HE USE OF THE SELECTIVE serotonin reuptake
inhibitors (SSRIs) has grown significantly
in the treatment of pediatric major depressive
disorder (MDD), owing, in part, to efficacy data
in adults, ease of dosing, and perception of good
tolerability and safety in overdose. However,
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recent availability of meta-analyses completed
by regulatory agencies of published and unpublished industry-sponsored trials, epidemiological studies of youth suicide and medication
use, and the Treatment for Adolescents with
Depression Study (TADS) (TADS Team 2004)
have expanded our knowledge-base regarding
the efficacy and safety of SSRIs in young patients.
Based on currently available data, we provide
in this paper a critical discussion of potential
risks and benefits of SSRIs in the treatment of
children and adolescents with depression.
Background and context
Fluoxetine, the first SSRI approved in the
United States for the treatment of MDD, was
made commercially available in 1987. As early
as 1991, the U.S. Food and Drug Administration (FDA) held a public meeting to address
concerns that fluoxetine was potentially contributing to suicidal behaviors in adults. An
analysis of data pooled from 17 double-blind
clinical trials was presented by fluoxetine’s
manufacturer, Eli Lilly & Co. (Indianapolis,
IN). This analysis showed a greater decline in
symptoms of suicidality endorsed on the
Hamilton Depression Scale by adult patients
taking fluoxetine than those taking placebo
(Beasley et al. 1991). Subsequently, reviews of
clinical trials submitted to the FDA involving
nine antidepressants and 48,000 subjects (77 of
whom completed suicide) did not find a statistically significant difference in the risk for suicide
or suicide attempt between SSRIs and placebo,
or between SSRIs and other types of antidepressants (Khan et al. 2003; Khan et al. 2000).
The early pediatric literature on the treatment
of MDD with SSRIs was primarily limited to
case reports and small, open-label trials. It
wasn’t until 1997 that the first randomized,
double-blind, placebo-controlled trial showing
the efficacy of fluoxetine in children and adolescents (age, 7–18 years) with MDD was published (Emslie et al. 1997). In this National
Institute of Mental Health (NIMH)-funded
study, 56% of the subjects in the fluoxetine
group had improved at the end of the 8-week
trial compared with 33% in the placebo group
(p < 0.05). In 1998, based, in part, on that trial,
the practice guidelines published by the Amer-
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ican Academy of Child and Adolescent Psychiatry (AACAP) recommended SSRIs as initial
therapy in the acute phase of MDD (Birmaher
et al. 1998). This was followed by an increase
in prescribing SSRIs for youths. The number of
adolescents who received an antidepressant at
the index visit of a new episode of depression
grew from 5% at that point in 1998 to 37% in
2002 (Valuck et al. 2004).
With the advent of the FDA Modernization
Act (U.S. Congress 1997), which provided 6
months of additional market exclusivity for
pediatric studies, the number of industrysponsored MDD studies in children and adolescents grew (Emslie et al. 2002; Wagner et al. 2003;
Wagner et al. 2004). Publications of industryconducted, double-blind, placebo-controlled
trials of fluoxetine, paroxetine, sertraline, and
citalopram reflected this expanding level of activity. Following two positive randomized clinical trials involving 315 youths 8–18 years of
age (Emslie et al. 2002; Emslie et al. 1997), the
FDA approved fluoxetine for the treatment of
pediatric MDD in January 2003. Fluoxetine remains the only drug that is FDA-approved for
the treatment of depression in children and adolescents. In fact, most of the pediatric trials in
depression have failed to discriminate between
active medication and placebo on primary efficacy measure. Whereas this situation is not
substantially different from that in adult depression, given the notoriously high rate of response on placebo, it must be pointed out that
a particular feature of the FDA pediatric exclusivity rule may contribute to it. In fact, the 6month additional exclusivity is granted for
merely conducting a pediatric trial and not
necessarily for showing efficacy.
Then, in mid-2003, the Medicine and Health
Care Products Regulatory Agency (MHRA) of
the British Department of Health issued a report
concluding that paroxetine was contraindicated
in patients with MDD under the age of 18. This
decision was based on an examination of proprietary data, including both published and
unpublished data, that demonstrated a slight
increase in suicidal ideation and behavior (suicidality) among patients randomized to paroxetine as compared with those who received
placebo (3.7% versus 2.5%) and a lack of statistically significant benefit.

SSRIs AND PEDIATRIC DEPRESSION

The MHRA notice proved to be the first in a
series of notices by both the FDA and MHRA
expressing concerns regarding antidepressants
in the treatment of pediatric depression. It also
marked the beginning of extensive analyses
conducted by both regulatory agencies and two
public hearings in 2004 regarding SSRIs and
suicidality, this time with a focus on the pediatric population.
In December 2003, the MHRA completed a
summary analysis of their data regarding antidepressant use in pediatric depression. They
reported that there was no evidence of efficacy
for any SSRI in pediatric depression, except for
fluoxetine. Additionally, the MHRA described
a rate of adverse events that exceeded those of
placebo in many trials, with specific concerns
regarding suicidality. The MHRA concluded
that even if the risks were minimal, if there is
no evidence of benefit for the other antidepressants, then the risk/benefit relationship for
these medications would be unacceptable.
In February 2004, the FDA convened a joint
meeting of their Psychopharmacologic Advisory Committee and Pediatric Subcommittee
of the Anti-Infective Drugs Advisory Committee in order to evaluate the use of antidepressants in children and adolescents. The goal of
this meeting was to review the safety and efficacy data available through controlled trials of
antidepressants in children and adolescents.
The FDA was particularly concerned with examining the adverse events data regarding the
emergence or occurrence of suicide-related
events, including suicidal thinking as well as
actual self-harm. In the course of this review, it
became apparent that there were marked differences in methods of data collection, coding,
and analyses of adverse event data across
studies. This necessitated a review and reclassification of the suicidality adverse events in
order to accurately assess the available data. In
March 2004, as these analyses were being conducted, the FDA issued a public health advisory, as an interim step, asking manufacturers
of 10 different antidepressant drugs to include
in their label a warning section recommending close scrutiny for worsening depression
or emergence of suicidality in adult and pediatric patients treated with these agents (FDA
2004a).
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In September 2004, the results of a metaanalysis of 24 controlled clinical trials of nine
antidepressants in approximately 4400 pediatric patients were presented at a public hearing. The 24 trials were conducted for various
indications, primarily MDD, but also for anxiety and attention-deficit/hyperactivity disorder (ADHD). Although no completed suicides
occurred in these trials, the cumulative risk for
suicidality when adverse events were collected
by spontaneous report was approximately 4%
on active medication versus approximately 2%
on placebo, resulting in a relative risk of approximately 2 and a risk difference of 2%
(Hammad 2004). When data was systematically collected utilizing rating scales at baseline and routinely throughout the trials, the
overall rates of treatment-emergent suicidality
and suicidal worsening were higher than was
reported using spontaneous adverse event reports, but there was no difference between the
rates in the placebo and active drug groups
(Hammad 2004).
Based on the recommendations of the committee, the FDA took the following four actions
(FDA 2004b). They issued a “black box” warning that antidepressant use in children was accompanied by an increased risk for suicidality.
The warning was not limited to SSRIs, but involved all antidepressants, and was not specific for depression, but included any use in
pediatric populations. Secondly, they required
a medication guide to accompany all prescriptions. The medication guide included information for parents regarding monitoring for
suicidality and adverse events with antidepressants. Thirdly, they established guidelines for
frequency of monitoring when initiating antidepressants. Face-to-face follow-up with the
clinician weekly for 4 weeks, then every other
week for 4 weeks, and then monthly. And finally, they initiated unit-of-use packaging to
ensure that every patient receives the medication guide each time a prescription is filled.
The findings regarding suicidality have forced
clinicians to carefully consider the existing data
on: (1) The efficacy of antidepressants in this
population, (2) the potential harm of these
medications, and (3) what the implications are
for the treatment of children and adolescents
in their own practice.
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Efficacy data
In 2004, the FDA reviewed both published
and unpublished data on the efficacy of SSRIs
in pediatric depression and concluded that only
3 (two fluoxetine and one citalopram) of 15 pediatric MDD trials showed evidence of efficacy,
defined as a statistically significant (p < 0.05)
superiority of active medication over placebo
on the primary outcome measure (Table 1).
(Note: The results of TADS were not yet available at the time this summary was prepared.)
Three other trials (Keller et al. 2001; Wagner et
al. 2003) were believed to provide some suggestion of potential benefit, but they did not
meet FDA guidelines for a “positive” efficacy
study. The trial of paroxetine (Keller et al. 2001)
was positive on several secondary endpoints,
though not on the primary outcome, while the
two trials of sertraline showed a positive pri-

mary endpoint only when their data were
pooled and analyzed (Wagner et al. 2003).
These data provide support for the FDA indication of fluoxetine for pediatric depression.
The summary of these data also highlight the
fact that the majority of studies conducted to
date on pediatric depression were unpublished
and that all of the unpublished studies were
negative studies (i.e., did not demonstrate a benefit of active medication compared to placebo
on the primary outcome measure).
Published versus unpublished data. Clinicians
and the general public receive their information on clinical trials through published data.
A meta-analysis assessed conclusions based on
published data and contrasted those to conclusions reached by combining published and
unpublished data (Whittington et al. 2004).

TABLE 1. PRIMARY OUTCOME RESULTS FOR ACUTE (8–12 WEEK) PLACEBO-CONTROLLED PEDIATRIC STUDIES OF
SSRIS AND RELATED SEROTONERGIC DRUGS IN MAJOR DEPRESSION

Drug
Paroxetine
Paroxetine
Paroxetine
Fluoxetine
Fluoxetine
Fluoxetine
Sertraline
Sertraline
Venlafaxine
Venlafaxine
Citalopram
Citalopram
Nefazodone
Nefazodone
Mirtazapine
Mirtazapine

Publication

N

Primary outcome
continuous
measurec

Keller et al. 2001
Berard et al. 2006
Emslie et al. in press
Emslie et al. 2002
Emslie et al. 1997
TADS 2004
Wagner et al. 2003
Wagner et al. 2003
Unpublished
Unpublished
Wagner et al. 2004
Unpublished
Unpublished
Unpublished
Unpublished
Unpublished

275
275d
203e
219
96
439
160
160
161
193
174
244
195
273
126
124

HAM-D
MADRS
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R
CDRS-R

Age
range
(years)
12–18
13–18
7–17
8–18
8–17
12–17
6–17
6–17
7–17
7–17
7–17
13–18
12–18
7–17
7–17
7–17

Outcome* (drug
versus placebo)
Negativea
Negative
Negative
Positive
Positive
Positive
Trend
Negativeb
Negative
Negative
Positive
Negative
Trend
Negative
Negative
Negative

Source: Adapted from Laughren TP. Memorandum, January 5, 2004: Background comments for February 2, 2004
Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the AntiInfective Drugs Advisory Committee (AC), Bethesda, MD.
*Positive (p # 0.05); negative (p $ 0.10); Trend (0.05 < p # 0.10) on primary efficacy outcome.
aKeller et al. 2001; positive on most secondary endpoints.
bWagner et al. 2003; positive on pooling of two studies.
cMany studies also included responder rate as a primary categorical outcome in addition to the continuous rating
of depressive symptoms.
SSRIs = selective serotonin reuptake inhibitors; HAM-D = Hamilton Depression Rating Scale; MADRS=
Montgomery-Åsberg Depression Rating Scale; CDRS-R = Childhood Depression Rating Scale—Revised.
d286 randomized, but only 275 analyzed.
e206 randomized, but only 203 analyzed.
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Five published, acute, randomized, placebocontrolled trials of SSRIs in pediatric depression were compared with all unpublished data
included in the United Kingdom’s Committee
on Safety of Medicines’ review. All of the fluoxetine trials had been published, and two trials
(Emslie et al. 2002; Emslie et al. 1997) supported its efficacy in pediatric major depression,
suggesting a favorable risk/benefit profile. The
published results of one paroxetine trial and
two sertraline trials suggested equivocal or
weakly positive efficacy which, in the case of
paroxetine, was not supported by two other
then-unpublished trials (Berard et al. 2006).
Likewise, efficacy of citalopram was supported
by one published trial (Wagner et al. 2004) but
not by an unpublished one (Table 1). For venlafaxine and mirtazapine, two unpublished trials
for each compound did not demonstrate efficacy. In the face of unproven efficacy and the
potential for suicidality as an adverse event,
the authors concluded that the risk/benefit profiles for paroxetine, sertraline, venlafaxine, and
mirtazipine were unfavorable (Whittington et
al. 2004; Whittington et al. 2005).
The discrepancies between published and
unpublished data highlight the potential for
biased reporting of positive versus negative
results. Whittington et al. (2005) expressed
concerns that clinical guideline development
and clinical decisions regarding treatment are
largely dependent on the evidence base established through peer-reviewed journals and
that nonpublication of trials could lead to erroneous recommendations for treatment.
TADS data. The Treatment for Adolescents
with Depression Study (TADS) is an NIMHsponsored multisite trial comparing fluoxetine,
cognitive behavioral therapy (CBT), their combination, and placebo in 439 adolescents with
a primary diagnosis of major depression (TADS
Team 2004). The acute-phase TADS results were
not available at the time of the initial FDA advisory committee meeting in February 2004,
but they were published and available by the
time the committee reconvened in September
of that year. TADS is significant in that it was
the largest acute treatment study of depression
in youths. Additionally, TADS had a psychosocial treatment arm, both stand alone and in
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combination with fluoxetine, which had not
been included in previous antidepressant trials.
TADS had two primary outcome measures,
the scalar Children’s Depression Rating Scale—
Revised (CDRS-R; Poznanski and Hartmut 1996)
total score and the end-of-treatment response
rate defined by a categorical Clinical Global
Impression—Improvement score (CGI-I) of
much or very much improved. CDRS-R adjusted
mean (standard deviation) scores at baseline,
week 6, and week 12 were: CBT with fluoxetine 60.79 (4.85), 38.10 (7.78), 33.79 (8.24); fluoxetine alone 58.94 (4.00), 39.80 (7.37), 36.30
(8.18); CBT alone 59.64 (4.52), 44.63 (8.30),
42.06 (9.18); placebo 61.18 (4.27), 44.90 (7.32),
41.77 (7.99). Pairwise contrasts on the CDRS-R
regression slope coefficients showed that combination treatment with fluoxetine and CBT was
statistically superior to placebo (p = 0.001),
CBT (p = 0.001), and fluoxetine (p = 0.02),
whereas fluoxetine alone was statistically superior to CBT (p = 0.01) but not placebo (p = 0.10).
Supporting analyses performed on the week
12 CDRS-R adjusted means demonstrated fluoxetine with CBT (p = 0.001) and fluoxetine
alone (p = 0.002) to be superior to placebo,
whereas CBT alone was not (p = 0.97). Fluoxetine with CBT was superior to CBT alone (p =
0.001) but not to fluoxetine alone (p = 0.13),
whereas fluoxetine alone was superior to CBT
alone (p = 0.001). The other primary efficacy
outcome measure, the CGI-I-defined rates of
response, showed that more patients were responders to combination therapy (71%) or fluoxetine (61%) than to CBT (43%) or placebo
(35%; p # 0.01) (TADS Team 2004).
Thus, on one of the two primary analyses,
fluoxetine approached statistical significance
compared to placebo, although it was significantly better than CBT. However, the preponderance of the evidence from the other positive
primary analysis and supporting analyses,
using end-of-treatment CDRS-R scores, supports, the use of fluoxetine alone in decreasing
depressive symptoms.
The clinical impact of treatment on outcome
was evaluated by calculating the effect size
and the number needed to treat (NNT) to each
additional responder, based on the adjusted
means. The effect size derived from the CDRSR was 0.98 for fluoxetine with CBT, 0.68 for
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fluoxetine alone, and 20.03 for CBT alone. Effect sizes from the odds ratio (OR) for the dichotomized CGI-I were 0.84 for fluoxetine with
CBT, 0.58 for fluoxetine alone, and 0.20 for CBT
alone. The NNT for the dichotomized CGI-I for
fluoxetine and CBT was 3 (95% Confidence Interval [CI], 2–4), for fluoxetine alone was 4
(95% CI, 3–8), and for CBT alone 12 (95% CI,
5–23). Thus, the largest study to date of adolescent depression provided clear evidence of
fluoxetine’s efficacy in adolescents with moderate to severe depression.
Summary. Based upon these clinical trials, fluoxetine does appear to have efficacy in the treatment of pediatric depression, with the majority
of the trials demonstrating positive results.
These data, combined with the TADS data suggesting that psychotherapy alone faired poorly
compared to fluoxetine and that the best treatment combination has fluoxetine as a component, would lend support to the use of
fluoxetine in the treatment of pediatric MDD.
Support for efficacy also exists for sertraline,
citalopram, and paroxetine. However, the efficacy signal for these drugs is weaker and inconsistent, as shown by the inability to replicate it in
other studies. It is entirely possible that this variability in outcome is similar to what is seen in
the adult literature, where antidepressants approved by the FDA for the treatment of adult
MDD frequently have as many negative as positive trials. Finally, no efficacy signal has
emerged for venlafaxine or mirtazapine.
Whether the discrepancy between the fluoxetine
and other SSRI’s data is better explained by ex-

perimental error owing to methodological factors in study design and conduct (more likely, as
evidenced by the variability in placebo response) or by substantive pharmacological differences (less likely) remains a matter of debate.
Safety data
Risk of treatment. In September 2004, when the
FDA presented results of their meta-analysis
of 25 trials plus TADS, safety data were presented in addition to the efficacy data (Hammad 2004). In order to make the clinical trial
datasets more uniform with respect to adverse
event reporting, an independent team of experts utilized a novel approach developed by
researchers at Columbia University to evaluate and recode all adverse events for suicidal
and self-injurious behaviors (suicide attempt,
preparatory acts, suicidal ideation, and so
forth). Following reclassification, 78 of the approximately 4400 subjects from these datasets
(1.7%) were coded as experiencing either suicidal behavior (n = 33) or suicidal ideation (n =
45). Once a uniform classification was applied,
relative risks for suicidal ideation and behavior were calculated by drug and by study indication (Table 2). There were no completed
suicides, and only venlafaxine and fluoxetine
in TADS exhibited a statistically significant signal for suicidality (suicide attempts or suicidal
ideation). The overall relative risk (RR) for suicidality was 1.66 (95% CI; 1.02, 2.68) for MDD
trials and 1.95 (1.28, 2.98) for all trials, all indications. The authors of the analysis concluded
that: “Although the difference is small, it seems

TABLE 2. OVERALL RELATIVE RISKS OF SUICIDAL BEHAVIOR OR IDEATION BY DRUGS IN MDD TRIALS AS DEFINED BY THE
COLUMBIA UNIVERSITY RECLASSIFICATION PROJECT (HAMMAD 2004)
Drug
Citalopram
Fluvoxamine
Paroxetine
Fluoxetine (including TADS)
Sertraline
Venlafaxine
Mirtazapine
Nefazodone
Bupropion

Relative risk (95% CI), MDD trials

Relative risk (95% CI), all trials, all indications

1.37 (0.53, 3.50)
No MDD trials
2.15 (0.71, 6.52)
1.53 (0.74, 3.16)
2.16 (0.48, 9.62)
8.84 (1.12, 69.51)
1.58 (0.06, 38.37)
No events
No MDD trials

1.37 (0.53, 3.50)
5.52 (0.27, 112.55)
2.65 (1.00, 7.02)
1.52 (0.75, 3.09)
1.48 (0.42, 5.24)
4.97 (1.09, 22.72)
1.58 (0.06, 38.37)
No events
No events

MDD = major depressive disorder; CI = Confidence Interval.
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likely that the effect is real, because the findings were statistically significant in aggregate
and are consistent across multiple studies of
various agents” (Brent 2004).
This issue can be analyzed in terms of “risk
difference,” which provides an estimate of the
absolute increase in risk of the event of interest
attributable to treatment, in this case, suicidality. This is calculated by subtracting the risk in
the placebo group from the risk in the active
drug group. The overall risk difference for the
SSRIs in the MDD trials is approximately 2%.
In other words, 2 patients of 100 treated with
an SSRI for major depression would be expected
to have an increase in suicidality during shortterm treatment attributable to the drug. Suicidality, when it did occur, was primarily ideation,
with only a minority of events involving actual suicide attempts (27 suicide attempts, 6
“preparatory actions),” and 45 suicidal ideation
events). Additional risk beyond that is inherent in the disorder being treated (Hammad 2004).
In addition to an increase in the risk of suicidality, SSRIs are almost twice as likely as
placebo to cause increased agitation and hostility during acute treatment (Table 3). At this
time, it is unclear whether the increased risk
for suicidality associated with these medications is mediated by the agitation and hostility
symptoms, but it is important for patients and
families to be aware of this potential.
FDA conclusions regarding risk. The advisory
committee to the FDA concluded that the ad-

TABLE 3. OVERALL RELATIVE RISK OF TREATMENTEMERGENT AGITATION OR HOSTILITY BY DRUG IN
MDD TRIALS (HAMMAD 2004)
Drug

Relative risk (95% CI), MDD trials

Citalopram
Paroxetine
Fluoxetine (does not include
TADS)
Sertraline
Venlafaxine extended-release
Mirtazapine
Nefazodone
All drugs

1.87 (0.34, 10.13)
7.69 (1.80, 32.99)
1.01 (0.40, 2.55)
2.92 (0.31, 27.83)
2.86 (0.78, 10.44)
0.52 (0.03, 8.27)
1.09 (0.53, 2.25)
1.79 (1.16, 2.76)

MDD = major depressive disorder; CI = Confidence
Interval.
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verse events reported voluntarily during clinical trials in aggregate did indicate an increased
risk of treatment-emergent suicidality. Although
there was variability in the adverse event data,
the committee was unable to conclude that
any single antidepressant was free of risk. The
committee suggested additional research is
needed to further delineate the risks and benefits of these drugs in pediatric patients with
psychiatric illness. Additional efficacy data and
more safety data focusing specifically on suicidality are needed. Long-term trials using
placebo and fluoxetine as controls, as well as
additional NIH projects aimed at improving
our understanding of the natural and longitudinal course of depression and suicidality,
would better inform clinicians how to diagnose
and treat pediatric depression. The risks associated with pharmacological and nonpharmacological interventions, as well as the risks of
not treating depressed children and adolescents, should also be assessed (FDA 2004b).
Since the FDA’s October 2004 “black box”
warning and additional recommendations regarding antidepressant use in children, other
regulatory bodies have also released warnings. In April 2005, the European Medicines
Agency issued a press release regarding their
review of SSRI and SNRI medicines in children
and adolescents (atomoxetine, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine,
mianserine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline and venlafaxine).
They recommended: “. . . strong warnings
across the whole of the European Union to
doctors and parents about these risks. Doctors
and parents will also be advised that these
products should not be used in children and
adolescents except for their approved indications.” Approved indications in the pediatric
population are limited to obsessive-compulsive
disorder (OCD) for a few of the agents and
ADHD for atomoxetine (European Medicines
Agency 2005).
TADS data pertaining to risk. TADS provided a
systematic approach to collecting data on suicidality, beginning at baseline and continuing
to all subsequent endpoints, which allows for
a longer-term assessment of the role of various
treatments on suicide. At baseline, clinically
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significant suicidal thinking was present in 29%
of the sample, as measured by the CDRS-R
suicide item and the Suicidal Ideation Questionnaire–Junior High School Version (SIQ-Jr;
Reynolds 1987). Suicidality declined significantly in all four treatment groups with fluoxetine plus CBT showing the greatest reduction
(p = 0.02). There were no completed suicides in
the course of the study, but 24 (5.5%) of the 439
TADS patients experienced a suicide-related
event. Seven (7) of the 24 suicide-related events
were suicide attempts (1.6% of the total sample). Four (4) of the attempts were by patients
assigned to fluoxetine and CBT, 2 to fluoxetine
alone, and 1 to CBT alone. None of the subjects
taking placebo attempted suicide.
Harm-related events, which included thoughts
or behaviors related to harm of self as well as
harm to others, occurred in 11.9% of those assigned to fluoxetine alone, 8.4% fluoxetine with
CBT, 4.5% CBT alone, and 5.4% placebo.
Overall, suicidality decreased with treatment.
Improvement was greatest for those receiving
combination treatment and least for those receiving fluoxetine alone. It is important to note
that, though fluoxetine did not appear to increase suicidal ideation, the harm-related adverse events did occur more frequently in
fluoxetine-treated patients (TADS Team 2004).
Epidemiological and observational data. Although
no causality can be determined, nonexperimental studies using community or observational
data offer a perspective complementary to the
information from controlled clinical trials of
antidepressant use in children and adolescents.
Whereas the pediatric use of antidepressants has substantially increased throughout
the previous decade, the overall youth suicide rates had been declining (Olfson et al.
2003). During 1992–2001, for example, the
overall suicide rate among persons 10–19
years of age declined from 6.2 to 4.6 per
100,000 population (CDC 2004). A significant
inverse relationship was also found between
regional rates of antidepressant medication
use and suicide rates of 10- to 19-year-old
youths in the United States in 1990–2000.
Each 1% increase in antidepressant use was
associated with a decrease of 0.23 suicides per
100,000 adolescents per year.
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Valuck et al. assessed antidepressant use in
youth by analyzing a large database of insurance claims from both commercial and Medicaid plans. They examined claims filed (January
1997 to March 2003) from various regions across
the United States on adolescents newly diagnosed with MDD who had at least 6 months of
follow-up data (Valuck et al. 2004). The database of 24,119 adolescents revealed crude suicide attempt rates, ranging from 0.0% to 2.3%.
Treatment with SSRIs (hazard ratio [HR] = 1.59;
CI, 0.70, 2.89), other antidepressants (HR =
1.03; CI, 0.43, 2.44), or multiple antidepressants
(HR = 1.43; CI, 0.70, 2.89) after index MDD diagnosis resulted in no statistically significant
increase in risk of suicide attempt. Thus, whereas
the SSRIs were associated with a numerically
higher risk of suicide attempt (HR 1.59), the increase failed to reach statistical significance.
Treatment with an antidepressant medication
for at least 180 days reduced the likelihood of a
suicide attempt, as compared to treatment
courses of less than 55 days (HR = 0.34; CI,
0.21, 0.55). The authors concluded that antidepressants had no statistically significant effects
on the likelihood of suicide attempts.
A review of National Vital Statistics from the
Centers for Disease Control and Prevention analyzed records of all U.S. individuals at the county
level who committed suicide between 1996 and
1998, examining the association between antidepressant prescription and suicide rate (Gibbons
et al. 2005). Change in prescription rates of tricyclic antidepressants (TCAs), SSRIs, and other
non-SSRI antidepressants from 1996 to 1998
were obtained for each county. The data demonstrated lower suicide rates in association with increased use of selective serotonin reuptake
inhibitors and new-generation non-SSRIs, compared to TCA use. Suicide rates tended to be
higher in counties with larger proportions of
TCA prescriptions. As the authors point out, this
type of data cannot demonstrate causal relationships because the higher number of TCA prescriptions may simply be a marker for counties
with more limited access to mental health care.
The higher rates of suicides with TCA prescriptions may also reflect the greater toxicity in overdose of TCAs. After adjusting for age, gender,
race, income, and county-to-county variability in
suicide rates, the overall relationship between all

SSRIs AND PEDIATRIC DEPRESSION

prescribed antidepressants and suicide rate was
not statistically significant (p = 0.14).
Jick et al. conducted an evaluation of antidepressant prescriptions utilizing a matched casecontrol design based on patients’ prescriptions/
diagnoses in the U.K. General Practice Research
Database (GPRD), 1993–1999 (Jick et al. 2004).
Data were collected on patients 10–69 years of
age treated with amitriptyline, fluoxetine, paroxetine, and dothiepin (reference group), assessing cases of nonfatal suicide behavior (ideation
or attempts) (n = 555), suicides (n = 17), and
controls (n = 2062) without suicidal behavior.
Compared to dothiepin, there was no statistically significant difference in suicidality with
one antidepressant compared to another, with
a range for the relative risk (RR) for nonfatal
suicide behavior of 0.83–1.29. Results were similar for patients 10–19 years of age, although
the sample of adolescent cases was small. There
were no suicides in the 10–19 year olds prescribed medication in this study population.
However, in reviewing the entire GPRD population from 1993 to 1999, 15 persons in this age
group had committed suicide, none of whom
had received an antidepressant drug.
Jick et al.’s evaluation of the time-course of
suicidal events is also of clinical interest. The
RR of nonfatal suicidal behavior/suicide was
highest for patients within 1–9 days of the antidepressant being prescribed (versus 90 days
or more). The RR for nonfatal suicidal behavior during this earlier time period was 4.07
(95% CI, 2.89–5.74), whereas the RR for suicide
was 38.0 (95% CI, 6.2–231). Although this could
indicate an exacerbation of suicidality during
the initiation of treatment, it could also be related to the acuity that prompted the initiation
of the treatment. It has been reported, even
prior to the antidepressant era, that people were
most likely to commit suicide as they were
coming out of a depressive episode.
Also, though it has been hypothesized that
abrupt discontinuation of antidepressants may
play a role in exacerbation of symptoms and
suicidality, there was no statistically significant
association between discontinuation of an antidepressant and nonfatal suicidal behavior.
Another way to determine whether SSRIs
are implicated in completed suicides is through
toxicological analysis of individuals dying from
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suicide. A study of suicide in more than 5000
adults found that, most often, antidepressants
had not been taken immediately before death,
even though the majority of the persons had
been depressed (Isacsson et al. 1997). A study
of 14,857 suicides and 26,422 other deaths in
Sweden (Isacsson et al. 2005) found that none
of the 15 suicides below the age of 15 years had
an SSRI detected on toxicology. In 15–19-yearold suicide victims, SSRIs had a lower relative
risk in suicides compared with non-SSRIs. These
findings do not support the suggestion that
SSRIs are triggering suicides in adults or youth.
In a study of 49 adolescent suicides in Utah,
24% had been prescribed antidepressants, but
none had tested positive for SSRIs at the time
of death (Gray et al. 2003). In a postmortem
study conducted on 66 suicides among persons under 18 years of age in New York City
from 1993 through 1998 (Leon et al. 2004), 54
(81.8%) had serum toxicological analysis for
antidepressants and an injury-death interval
of 3 days or less. Imipramine was detected in 2
victims and fluoxetine in another 2 (total 10%).
None of the other 90% of suicides had antidepressants detected. Most postmortem studies
in adults have found that over 80% of depressed
patients at the time of suicide are not on antidepressants.
Risk of nontreatment. When weighing the potential risks and benefits of treatment, it is also
important to consider the risk of not treating
MDD. Suicide is the third-leading cause of
death among adolescents 15–19 years of age,
and fourth-leading cause of death among 10to 14 year olds (Anderson 2002). The depressed
pediatric subjects followed by Fombonne et al.
into adulthood demonstrated a suicide risk of
2.45%, with 44.3% of the sample attempting suicide once in their lives (Fombonne et al. 2001).
Weissman et al. also found an elevated risk
of suicide and comorbidity in long-term follow-up studies of depression. During a period
spanning approximately 10 years between adolescence and early adulthood, they estimated a
5-fold increased likelihood of suicide attempt
associated with pediatric depression (Weissman
et al. 1999a; Weissman et al. 1999b). Prepubertal children with an earlier age of MDD onset
are also at increased risk for substance abuse,
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conduct disorder, overall impaired functioning, and need for long-term psychiatric and
medical services (Weissman et al. 1999b). Clinical outcomes in adulthood of adolescent onset
MDD demonstrated a high rate of suicide (7.7%)
and a 5-fold increase for a first suicide attempt
(Weissman et al. 1999a).
Unfortunately, the available treatment interventions have limited data on acute efficacy
and unproven effectiveness in improving the
long-term outcome of the disorder. Nonetheless, fluoxetine remains the most effective acute
intervention, either alone or in combination
with psychotherapy, for decreasing depressive
symptoms in adolescents suffering from moderate to severe depression. However, specialized psychotherapy alone does not seem to be
a valid therapeutic option for these moderately to severely depressed patients (TADS
Team 2004).
Summary. Analyses of suicidality adverse
events collected in the pediatric antidepressant trials have demonstrated an elevation in
suicidality when placebo was compared to
active medication. Systematic and repeated
assessments of suicidality using symptom
rating scales, however, have not supported
this finding. In fact, when these data were
collected in TADS at baseline, 6 weeks, and
12 weeks, all four treatment groups demonstrated a decline in suicidality, with the
greatest decline occurring in the group receiving fluoxetine with CBT. Also of interest
are the epidemiological and observational
data, which demonstrate an increase in the
use of SSRIs in the pediatric population but
no corresponding increase in completed suicides. In fact, studies have generally identified an inverse correlation, both nationally
and regionally, with suicide and antidepressant usage.

DISCUSSION
The pharmacological treatment of pediatric
depression has recently undergone intensive
scrutiny and discussion. Throughout the process, a better understanding of the potential
risks and benefits has evolved. There is a clear

need for additional clinical trials to systematically assess these issues, but this will obviously be an extended process. At this point,
the task for the clinician is to be aware of what
information is available and to make an informed decision regarding the balance between
potential benefits and risks when deciding upon
a treatment plan for the individual patient.
Various statistical methods can be employed
to assess benefit versus risk (Whittington et al.
2004). However, interpretation of these data
must ultimately be conducted in a clinical context. The decision as to whether the calculated
risk is favorable, for example, to induce one
adverse event for every 10 patients showing
improvement, is dependent on the severity of
the event and the presence of better alternatives.
It is possible that, at times, the ease of use,
tolerability, and perceived efficacy of the SSRIs
in clinical practice led to an overly casual pattern of usage in treating pediatric disorders.
Despite increasing rates of antidepressant usage,
it is difficult to argue that these medications
are overprescribed, as the ratio of prescriptions for the treatment of depression to prevalence of MDD remains much less than one.
Considerable evidence supports the use of
fluoxetine for pediatric MDD. However, even
fluoxetine carries risks, which must be considered in the risk/benefit analysis and treatment
planning. The TADS Team concluded that:
“The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major
depressive disorder” (TADS Team 2004). Combination therapy may be the best treatment for
teenagers with major depression, especially
when the depression is moderate to severe and
there is a history of past or present suicidality.
Whereas CBT alone was not better than
placebo, and, by most measures, was inferior
to combination treatment or fluoxetine alone,
it proved to be a useful adjunct to pharmacotherapy. CBT also demonstrated usefulness,
both alone and in combination with fluoxetine,
in the reduction of suicidal thoughts and behaviors. Because nearly 40% of depressed
teens do not respond to fluoxetine and others
aren’t able to tolerate it, treatments other than
fluoxetine should continue to be studied and
be made available.
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What we still do not know
Despite a recent expansion of data, our
knowledge base about the efficacy and safety
of SSRIs remains limited, with many unanswered questions:
•
• Are there clinically significant differences
between prepubertal and adolescent depression with respect to antidepressant
treatment efficacy and safety? If so, what
are the underlying causes of such differences?
• Are there clinically significant differences
among SSRIs and similarly related antidepressants with respect to efficacy and/or
safety?
• What accounts for the apparent discrepancy between the efficacy of SSRIs in adult
depression and the much weaker and inconsistent data in the pediatric population?
Is pediatric depression a substantively different condition than depression in adults?
There is a need to better understand the
longitudinal course of child and adolescent depression and its relationship to adult
major depression. Are the assessment
methods used in pediatric clinical trials
not sufficiently sensitive and specific for
measuring depression? Because there have
been a significant number of adult studies
but very few pediatric studies, is the lack
of positive pediatric studies simply a manifestation of fewer studies conducted?
• How can one best interpret “negative” trials
of antidepressants? It is important to note
that negative studies do not necessarily
prove a lack of efficacy. The placebo response in depression trials can be significant, owing, in part, to study design and
can potentially lead to an inability to demonstrate efficacy, even for a robust treatment. But negative trials cannot be fully
dismissed either, especially when they are
properly designed and statistically powered to reject the null hypothesis.
• Likewise, are there real differences in
safety of SSRIs between children/adolescents and adults? Why is an association
between SSRIs and suicidality detectable
in pediatric data, but not in the much

•

•

•

•

larger database of adult studies (Martinez
et al. 2005)? Will closer examination of
adult data reveal that youth are not specifically at risk and the risk regarding suicidality is ubiquitous across developmental
stages?
Which subgroup of depressed youths are
the best candidates for antidepressant treatment and which ones are likely to respond
to nonpharmacological interventions?
Randomized clinical trials rely on “suicidality” measures, such as suicidal ideation
and suicidal attempts. But what is the relationship between suicidality and completed suicide? Can increased risk for
suicidality be considered a valid marker
for increased risk for suicide? Epidemiologically, the relationship among suicidal
ideation, suicidal attempts, and suicide is
not linear, as suicide has decreased in the
last 10 years, but rates of suicidal ideation
and suicidal attempts have not (Kessler et
al. 2005).
What is the most effective way to monitor
patients for safety during treatment with
antidepressants? The FDA has issued specific recommendations that the clinician
should see children and adolescents on a
weekly basis during the 1st month of treatment. This recommendation is based on
usual practice in clinical trials, but no empirical evidence currently supports this
schedule of visits over less intensive but
potentially equally effective approaches
(e.g., biweekly visits, with weekly phone
contacts between visits).
We know from controlled studies that there
can be an increased risk of self-harm and
aggression in the short term, but we do
not know if the risk disappears or additional benefits emerge beyond 2–3 months
of treatment.
How can a clinician distinguish suicidality
that is causally related to the treatment
delivered from suicidality that emerges as
a result of the underlying illness? Stopping antidepressant treatment with the
emergence of worsening suicidality may
become the norm with the current warnings. However, recent FDA analyses indicate that only 50% of emerging suicidality
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is related to prescribed treatment and 50%
to other causes, with no way for the clinician to distinguish between the two. This
could lead to premature discontinuation
of an effective treatment. Additionally, what
should a clinician do after a treatment is
discontinued for suicidality? Does one
make a determination that a child is “allergic” to SSRIs and try nondrug strategies,
or challenge with a second SSRI, or prescribe alternatively untested medication
or psychotherapy?
The recent concerns about SSRIs have illustrated the value of having conducted 15 randomized clinical trials in pediatric depression
in a relatively short period of time. Without
data from these trials, no assessment of benefit
and risk could have been even attempted. However, studies with small sample sizes, such as
those conducted to date, will never answer important safety questions where the outcomes
of interest occur infrequently. It is not practical
to design a randomized clinical trial with suicide as an endpoint, owing to the sample size
and duration of a study necessary to evaluate
the risk of such an uncommon event. Moreover, establishing relative risk by drug, drug
class, subgrouping (e.g., age, gender, disorder)
and understanding some aspect of mechanism
(e.g., activation) requires very large samples.
Hence, practical clinical trials (March et al. 2004;
March et al. 2005) are essential if we are to
learn more about predictors and management
of risk. It is extraordinary that no one has risen
to this challenge, to address this significant
public health issue, and advocates for depressed youths shouldn’t avoid saying so.

CONCLUSIONS
Essentially, the present use of SSRIs in the
treatment of pediatric depression is an informed consent issue. The clinician must openly
discuss the risks and benefits of the various
treatment options with the youth and parents
prior to the selection of the most appropriate
treatment for that specific child. With the increase in clinical trials and epidemiological

databases, clinicians can more accurately discuss the risk/benefit relationships. However,
much remains to be discovered and learned
about the treatment of pediatric depression.
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